<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Following initial graft rejection, a second attempt at allogeneic immunotherapy is often contemplated, but data on the success is limited </plain></SENT>
<SENT sid="1" pm="."><plain>We therefore report on 11 patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, <z:e sem="disease" ids="C0007134" disease_type="Neoplastic Process" abbrv="">renal cell cancer</z:e> or marrow failure who underwent a second reduced-intensity regimen for primary or secondary graft failure </plain></SENT>
<SENT sid="2" pm="."><plain>Nine of the 11 patients initially engrafted with the second attempt including two of four who used the same donor </plain></SENT>
<SENT sid="3" pm="."><plain>One of the patients engrafted after the third attempt using a different donor and conditioning regimen </plain></SENT>
<SENT sid="4" pm="."><plain>There were two treatment-related <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Four patients died from progressive disease 1-9 months after the second transplant </plain></SENT>
<SENT sid="6" pm="."><plain>Two patients are still in recovery phase less than 1 year from the second transplant </plain></SENT>
<SENT sid="7" pm="."><plain>Long-term remission is possible and three patients are alive in complete remission </plain></SENT>
</text></document>